present
human
proteas
list
degradom
databas
quesada
et
al
divid
five
class
base
catalyt
mechan
major
belong
famili
metallo
member
serin
enzym
cystein
proteas
member
addit
threonin
aspartyl
proteas
known
far
proteas
welldrugg
target
numer
smallmolecul
proteas
inhibitor
approv
past
ten
inhibitor
angiotensinconvert
enzym
ace
turk
well
neprilysin
enkephalinas
inhibitor
prodrug
sacubitril
howel
cameron
racecadotril
acetorphan
target
metalloproteas
ace
blocker
sacubitril
suitabl
longterm
usag
antihypertens
drug
wherea
racecadotril
approv
antidiarrh
drug
despit
limit
use
treatment
high
blood
pressur
also
possibl
aliskiren
smallmolecul
inhibitor
aspart
proteas
renin
wood
et
al
numer
synthet
inhibitor
trypsinlik
serin
proteas
tlsp
thrombin
argatroban
dabigatran
etexil
bivalirudin
factor
xa
rivaroxaban
apixaban
edoxaban
betrixaban
use
anticoagul
straub
et
al
except
argatroban
bivalirudin
clot
proteas
inhibitor
oral
avail
suit
longterm
use
prevent
stroke
eg
patient
suffer
atrial
fibril
meanwhil
ten
gliptin
approv
variou
countri
gliptin
class
oral
hypoglycem
drug
treatment
diabet
mellitu
type
target
serin
proteas
dipeptidyl
peptidas
therebi
reduc
degrad
incretin
hormon
lead
enhanc
insulin
secret
scheen
proteasom
inhibitor
bortezomib
adam
carfilzomib
kortuem
stewart
use
patient
multipl
myeloma
first
approv
drug
target
threonin
proteas
meanwhil
two
addit
proteasom
inhibitor
ixazomib
oprozomib
obtain
orphan
drug
statu
manasanch
orlowski
besid
address
human
proteas
numer
inhibitor
aspartyl
proteas
hiv
ghosh
et
al
serin
proteas
hepat
c
viru
mccauley
rudd
market
except
inhibitor
routin
use
combin
drug
singl
agent
despit
larg
effort
cystein
proteas
inhibitor
approv
far
one
advanc
inhibitor
papainlik
bonedegrad
proteas
cathepsin
k
nitril
deriv
odanacatib
develop
treatment
osteoporosi
base
clinic
phase
iii
trial
high
efficaci
increas
bone
miner
densiti
reduc
risk
fractur
initi
report
well
good
safeti
profil
chapurlat
howev
develop
stop
end
due
slightli
increas
risk
stroke
mullard
cathepsin
k
inhibitor
like
nitril
balicatib
fail
phase
ii
due
complic
skin
fibrosi
et
al
runger
et
al
despit
lack
approv
cystein
proteas
inhibitor
mani
exampl
confirm
suitabl
least
proteas
excel
drug
target
also
appli
numer
host
proteas
involv
variou
step
propag
cycl
certain
virus
inhibit
host
enzym
could
advantag
compar
classic
address
viral
target
due
low
risk
rapid
drug
resist
howev
side
effect
may
occur
target
host
enzym
requir
normal
physiolog
process
moreov
host
proteas
belong
famili
structur
close
relat
enzym
therefor
might
challeng
address
singl
target
without
affect
famili
member
order
avoid
side
effect
narrow
therapeut
window
therefor
advis
develop
host
proteas
inhibitor
mainli
combin
therapi
enabl
use
lower
drug
dose
follow
section
numer
exampl
antivir
activ
inhibitor
mainli
address
human
serin
proteas
provid
addit
structur
aspect
proteaseinhibitor
complex
discuss
although
first
approv
inhibitor
ace
thrombin
discov
long
target
structur
determin
subsequ
success
develop
field
proteas
inhibitor
strongli
support
avail
crystal
structur
import
prerequisit
ration
structurebas
drug
design
concept
ha
cleavag
inhibit
realist
antivir
strategi
support
studi
broadspectrum
inhibitor
aprotinin
mice
ovcharenko
zhirnov
zhirnov
et
al
kunitztyp
inhibitor
also
known
bpti
isol
bovin
lung
rel
well
toler
anim
human
inhibit
numer
trypsinlik
serin
proteas
trypsin
plasmin
matriptas
plasma
kallikrein
ascenzi
et
al
complex
trypsin
shown
fig
trasylol
intraven
use
mani
year
reduc
periop
bleed
open
heart
surgeri
withdrawn
market
becam
clear
associ
increas
number
death
compar
treatment
standard
antifibrinolyt
fergusson
et
al
nonhuman
protein
may
caus
hypersensit
reaction
cardiac
surgeri
although
risk
anaphylact
reaction
firsttim
exposur
low
might
increas
reexposur
levi
adkinson
howev
applic
aprotinin
influenza
form
aerosol
significantli
lower
dose
minim
side
effect
zhirnov
et
al
addit
aprotinin
variant
stronger
kallikrein
similar
plasmin
inhibit
develop
exhibit
reduc
immunogen
chimpanze
apel
et
al
antivir
potenc
influenza
recent
also
demonstr
endogen
proteinac
inhibitor
hepatocyt
growth
factor
activ
inhibitor
hamilton
et
al
type
transmembran
protein
contain
two
kunitz
domain
inhibit
numer
trypsinlik
serin
proteas
includ
hepatocyt
growth
factor
activ
matriptas
szabo
et
al
hepsin
trypsin
prostasin
liu
et
al
sunflow
trypsin
inhibitor
bicycl
provid
also
excel
scaffold
design
serin
proteas
inhibitor
luckett
et
al
fig
one
smallest
natur
occur
peptid
proteas
inhibitor
compris
typic
bowmanbirk
motif
serin
proteas
inhibitor
bbi
characterist
disulfidebridg
loop
contain
residu
li
et
al
mcbride
et
al
inhibitor
stabil
addit
headtotail
backbon
cycliz
ntermin
ctermin
residu
inhibit
trypsin
matriptas
k
valu
pm
luckett
et
al
nm
long
et
al
respect
initi
crystal
complex
trypsin
luckett
et
al
bind
mode
determin
also
activ
site
matriptas
fig
yuan
et
al
contrast
trypsin
complex
amino
group
make
waterbridg
interact
bottom
pocket
matriptas
form
direct
contact
carboxyl
group
also
interact
side
chain
carbonyl
oxygen
adjac
second
water
molecul
fig
numer
analogu
made
instanc
convers
simpl
truncat
monocycl
analogu
provid
k
valu
nm
matriptas
fittler
et
al
bicycl
analogu
contain
sidechaintotail
cycliz
even
potent
inhibit
constant
nm
fittler
et
al
howev
despit
excel
potenc
none
sfti
analogu
test
antivir
activ
high
molecular
weight
aprotinin
sfti
analogu
mainli
inhibit
extracellular
ha
process
rather
unlik
substanti
amount
compound
enter
cell
block
ttsp
secretori
pathway
despit
limit
aerosol
formul
aprotinin
develop
approv
russia
treatment
mildtomoder
influenza
infect
zhirnov
et
al
describ
case
mammalian
iav
lpaiv
monobas
progeni
particl
assembl
still
contain
uncleav
therefor
requir
activ
extracellular
enzym
sensit
aprotinin
contrast
previou
report
recent
find
reveal
monobas
process
intracellular
compart
without
need
extracellular
process
et
al
suggest
small
amount
aprotinin
reach
intracellular
target
achiev
antivir
efficaci
zhirnov
et
al
although
therapeut
use
peptid
drug
vliegh
et
al
biolog
includ
recombin
enzym
hormon
antibodi
steadili
increas
meanwhil
well
establish
treatment
synthet
smallmolecul
drug
offer
signific
advantag
produc
low
cost
larg
quantiti
offer
possibl
oral
administr
neglig
risk
allerg
reaction
initi
studi
weak
antivir
effect
treatment
eca
acid
fig
observ
mice
infect
iav
includ
plasmindepend
wsn
strain
zhirnov
et
al
b
due
small
size
eca
bind
effici
activ
site
trypsinlik
proteas
reduc
mainli
activ
plasminogen
block
lysin
bind
site
kringl
domain
plasminogen
alhorani
desai
pronounc
protect
effect
also
observ
iavinfect
mice
treat
cocktail
benzenesulfonylfluorid
aebsf
paminobenzamidin
pab
prior
infect
compound
rel
unspecif
proteas
inhibitor
occupi
pocket
trypsinlik
serin
proteas
aebsf
lead
coval
sulfonyl
activesit
side
chain
secondord
inactiv
constant
k
trypsin
pab
act
revers
competit
inhibitor
k
valu
two
threedigit
micromolar
rang
depend
specif
target
et
al
although
aebsf
stabl
buffer
relat
phenylmethan
sulfonylfluorid
pmsf
also
suscept
hydrolysi
aqueou
media
power
et
al
suitabl
develop
deriv
classic
activesit
titrant
pnitrophenylpguanidinobenzo
chase
shaw
includ
compound
like
camostat
nafamostat
fujii
hitomi
inhibit
numer
trypsinlik
serin
proteas
coval
acyl
activesit
provid
rel
stabl
acylenzym
complex
compound
activ
numer
monobas
iav
ibv
strain
hosoya
et
al
lee
et
al
someya
et
al
suffer
instabl
ester
bond
aqueou
media
circul
min
intraven
applic
camostat
man
midgley
et
al
short
halflif
also
report
nafamostat
although
could
advantag
certain
applic
notabl
nafamostat
wide
use
anticoagul
hemodialysi
patient
tendenc
bleed
han
et
al
although
antivir
efficaci
demonstr
eca
ligand
stronger
potenc
achiev
compound
also
address
adjac
bind
site
trypsinlik
host
proteas
possess
rel
welldefin
region
often
name
proxim
distal
bind
pocket
respect
therefor
substrat
analogu
coupl
ctermin
decarboxyl
arginin
mimet
stabil
noncleav
scaffold
eg
arginylketon
moieti
warhead
target
activesit
serin
wellsuit
mimet
target
trypsin
furinlik
pc
group
anchor
make
numer
polar
interact
residu
bottom
exit
pocket
fig
exhibit
prefer
special
trypsinlik
serin
proteas
within
inhibitor
type
improv
select
individu
famili
member
partial
achiev
via
andor
residu
substrat
analogu
structur
strictli
requir
amino
acid
lconfigur
wherea
dconfigur
often
prefer
side
chain
address
characterist
distal
bind
pocket
found
mostli
welldefin
trypsinlik
serin
proteas
contrast
side
chain
natur
lconfigur
residu
direct
toward
solvent
make
fewer
bind
contribut
interestingli
backbon
residu
involv
short
antiparallel
interact
highli
conserv
glycin
posit
proteas
domain
irrespect
l
dconfigur
amino
acid
far
crystal
structur
ttsp
involv
ha
cleavag
like
hat
avail
howev
countless
crystal
structur
inhibitor
type
complex
numer
trypsinlik
serin
proteas
elucid
exampl
fig
show
bind
mode
substrat
analogu
inhibitor
fig
complex
trypsin
indic
characterist
bind
pocket
maiwald
et
al
inhibitor
type
could
refin
follow
wellestablish
prodrug
strategi
use
develop
oral
avail
thrombin
inhibitor
ximelagatran
gustafsson
et
al
convers
pk
hydroxyamidin
pk
reduc
strongli
basic
charact
group
improv
bioavail
inhibitor
enzym
system
found
liver
organ
kidney
lung
brain
intestin
consist
cytochrom
nadhdepend
cytochrom
reductas
enzym
involv
reduct
nhydroxyl
compound
clement
due
similar
architectur
pocket
trypsinlik
serin
proteas
challeng
achiev
pronounc
select
individu
proteas
within
inhibitor
scaffold
although
compound
rel
select
matriptas
inhibitor
k
nm
show
reduc
affin
clot
proteas
thrombin
k
nm
factor
xa
k
nm
maiwald
et
al
potenc
inhibitor
type
enhanc
elong
suitabl
residu
prefer
sulfonyl
group
wherea
one
oxygen
atom
interact
amid
nh
inhibitor
contain
dconfigur
residu
ntermin
coupl
benzylsulfonyl
group
induc
turnlik
inhibitor
backbon
conform
bound
target
ntermin
benzyl
group
bind
shallow
subpocket
adjac
site
come
close
van
der
waal
contact
phenyl
ring
fig
disulfid
bridg
inhibitor
somewhat
select
fxa
inhibitor
k
nm
schweinitz
et
al
due
presenc
glycin
posit
inhibit
also
trypsin
matriptas
inhibit
constant
nm
nm
respect
replac
glycin
prolin
posit
lead
rel
nonselect
inhibitor
bapa
possess
one
twodigit
nanomolar
potenc
clot
proteas
thrombin
fxa
plasma
kallikrein
pk
fibrinolyt
plasmin
ttsp
hat
matriptas
hellstern
et
al
maiwald
et
al
sielaff
et
al
signific
antivir
effect
found
bapatr
cell
cultur
infect
numer
monobas
iav
strain
et
al
et
al
sielaff
et
al
mani
analogu
inhibitor
scaffold
differ
andor
residu
test
less
effect
bapa
data
publish
seem
compound
broader
target
spectrum
exhibit
advantag
antivir
profil
tendenc
confirm
promis
result
obtain
rel
nonselect
inhibitor
aprotinin
otherwis
less
select
inhibitor
also
target
numer
clot
proteas
might
suffer
narrow
safeti
profil
due
potenti
bleed
complic
iv
treatment
side
effect
might
reduc
compound
inhal
describ
aprotinin
notabl
bapa
well
toler
bleomycininduc
fibrosi
model
mice
appli
aerosol
via
microspray
data
publish
principl
possibl
replac
ctermin
residu
substrat
analogu
inhibitor
numer
altern
group
known
field
thrombin
fxa
inhibitor
straub
et
al
besid
basic
group
mani
chlorosubstitut
aromat
residu
use
exampl
inhibitor
develop
sisay
et
al
chlorin
address
highli
conserv
side
chain
found
back
pocket
wherea
aminomethyl
group
come
pocket
bind
provid
enhanc
inhibitori
potenc
thrombin
fxa
lead
reduc
inhibit
hat
matriptas
plasmin
sever
trypsinlik
serin
proteas
howev
weak
antiinfluenza
activ
found
compound
suggest
relev
hacleav
host
proteas
suscept
chlorosubstitut
aromat
structur
anoth
strategi
design
coval
inhibitor
singh
et
al
coval
bond
irrevers
form
eg
serin
proteas
inactiv
chloromethyl
keton
cmk
power
et
al
although
cmk
use
tool
initi
biochem
experi
structur
analysi
suitabl
drug
develop
due
stabil
select
problem
elig
approach
incorpor
electrophil
warhead
also
form
coval
revers
bond
target
achiev
coupl
substrateanalogu
segment
boroarginin
argin
group
keton
electrophil
group
attack
activesit
serin
provid
coval
boron
ester
hemiacet
hemiketallik
complex
form
coval
bond
significantli
improv
affin
inhibitor
argin
arginylketonederiv
thrombin
inhibitor
reach
preclin
earli
clinic
develop
steinmetz
et
al
stop
due
discoveri
suit
noncoval
inhibitor
like
melagatran
contain
residu
argin
deriv
acyl
ntermin
abzfluorophor
fig
describ
inhibitor
hat
k
nm
wysocka
et
al
second
aldehyd
deriv
contain
unusu
dialkyl
residu
inhibit
matriptas
inhibit
constant
nm
reduc
prostat
cancer
growth
xenograft
mice
model
galkin
et
al
howev
none
aldehyd
test
antivir
potenti
reus
revers
arginyl
keton
inhibitor
ttsp
start
compound
fig
although
much
stronger
matriptas
inhibitor
k
pm
potent
inhibit
addit
trypsinlik
serin
proteas
like
hepsin
hat
trypsin
k
valu
nm
colombo
et
al
compound
reduc
breast
cancer
progress
mice
zoratti
et
al
inhibit
iav
propag
human
cell
beaulieu
et
al
postul
antivir
efficaci
due
matriptas
inhibit
howev
sinc
inhibitor
concentr
use
well
k
valu
relat
proteas
conceiv
inhibit
addit
target
contribut
observ
antivir
effect
numer
analogu
modifi
peptid
segment
like
compound
k
valu
matriptas
nm
target
also
hepsin
hepatocyt
growth
factor
activ
hgfa
prepar
tumor
treatment
regul
iron
overload
test
influenza
virus
far
duchen
et
al
han
et
al
suitabl
scaffold
noncoval
inhibitor
trypsinlik
serin
proteas
tertiari
amid
sulfonyl
origin
develop
inhibit
trypsin
thrombin
upa
use
design
matriptas
inhibitor
steinmetz
et
al
et
al
except
class
compound
provid
rel
broadspectrum
inhibitor
target
numer
trypsinlik
serin
proteas
upa
inhibitor
et
al
fig
combin
prodrug
capecitabin
reach
clinic
develop
tumor
therapi
setyonohan
et
al
moreov
oral
avail
formul
form
hydroxyamidino
prodrug
mesupron
also
reach
clinic
phase
ii
studi
indic
pancrea
breast
cancer
suggest
inhibitor
type
suitabl
drug
develop
otherwis
compound
moder
inhibitor
numer
trypsinlik
serin
proteas
includ
matriptas
k
valu
close
steric
demand
rigid
triisopropylphenylsulfonyl
tip
group
fulli
occupi
distal
bind
pocket
usual
way
setyonohan
et
al
et
al
significantli
improv
select
matriptas
inhibit
k
nm
achiev
inhibitor
ntermin
target
distal
pocket
like
involv
interact
matriptas
steinmetz
et
al
howev
tribas
strongli
polar
charact
limit
membran
permeabl
bioavail
compound
therefor
number
basic
group
stepwis
reduc
provid
compound
contain
ntermin
substitut
group
analogu
inhibit
matriptas
similar
inhibit
constant
nm
nm
respect
hammami
et
al
meyer
et
al
also
rel
potent
thrombin
inhibitor
k
nm
poor
inhibitor
hat
k
replac
ctermin
amino
group
urea
portion
provid
monobas
analogu
hammami
et
al
k
nm
matriptas
nm
thrombin
compound
fig
reduc
propag
variou
lpaiv
strain
monobas
ha
cleavag
site
infect
cell
baron
et
al
meyer
et
al
instanc
treatment
compound
inhibit
multipl
cycl
replic
iav
strain
cell
meyer
et
al
identifi
major
hacleav
proteas
et
al
far
crystal
structur
avail
protein
data
bank
therefor
gener
homolog
model
complex
inhibitor
use
swissmodel
http
swissmodelexpasyorg
biasini
et
al
model
superimpos
crystal
structur
inhibitor
complex
thrombin
pdb
hammami
et
al
subsequ
delet
thrombin
structur
inhibitor
energi
minim
activ
site
use
softwar
molecular
oper
environ
moe
model
show
expect
polar
contact
known
numer
crystal
structur
sulfonyl
complex
trypsin
renatu
et
al
upa
zeslawska
et
al
matriptas
steinmetz
et
al
fig
benzamidin
bind
bottom
pocket
wherea
backbon
amid
nh
carbonyl
oxygen
make
short
antiparallel
interact
one
sulfonyl
oxygen
bind
nh
note
complex
substrat
analogu
inhibitor
address
backbon
nh
carbonyl
residu
indic
complet
differ
bind
mode
inhibitor
type
drug
develop
strongli
focus
design
nonpeptid
smallmolecul
inhibitor
usual
stabl
peptid
inhibitor
possess
longer
halfliv
offer
better
chanc
oral
bioavail
hundr
highli
potent
nonpeptid
inhibitor
target
clot
proteas
avail
wherea
ttsp
inhibitor
type
describ
far
work
done
field
matriptas
inhibitor
fig
bisbenzamidin
k
valu
nm
enyedi
et
al
enhanc
potenc
k
nm
describ
analogu
goswami
et
al
tribas
compound
show
improv
matriptas
inhibit
k
valu
nm
nm
respect
goswami
et
al
less
rigid
core
segment
use
design
tribas
inhibitor
inhibit
matriptas
k
valu
nm
furtmann
et
al
group
korea
report
discoveri
deriv
inhibitor
ic
valu
kang
et
al
respect
surprisingli
also
mucolyt
cough
suppress
bromhexin
describ
inhibitor
ic
bind
mode
bisbenzamidin
sever
tribas
analogu
complex
matriptas
determin
crystal
structur
analysi
complex
inhibitor
shown
fig
one
benzamidin
occupi
site
second
target
distal
pocket
wherea
aminocyclohexyl
group
direct
toward
matriptas
involv
direct
polar
contact
due
lack
experiment
structur
bind
mode
compound
trust
predict
nonpeptid
inhibitor
develop
address
ttsp
target
tumor
treatment
goswami
et
al
kang
et
al
luca
et
al
although
might
also
suitabl
indic
besid
influenza
virus
viral
pathogen
also
suitabl
target
inhibitor
trypsinlik
serin
proteas
tlsp
exampl
present
follow
paragraph
paramyxovirida
contain
two
surfac
glycoprotein
receptorbind
protein
hn
h
g
fusion
protein
f
contrast
orthomyxovirida
fusion
viral
membran
host
cell
membran
occur
endosom
activ
f
protein
mani
paramyxovirus
induc
fusion
viru
envelop
plasma
membran
precursor
human
parainfluenza
viru
cleav
monobas
sequenc
typic
tlsp
diederich
maisner
caus
respiratori
infect
croup
especi
among
young
children
principl
abovedescrib
inhibitor
could
also
suitabl
treatment
hpiv
infect
paramyxovirus
measl
viru
mump
viru
activ
furin
wherea
nipah
viru
cleav
cathepsin
l
consequ
furin
cathepsin
l
inhibitor
suitabl
treatment
viru
infect
spike
surfac
protein
respiratori
coronavirus
cov
also
synthes
inact
precursor
protein
activ
host
proteas
ntermin
unit
cleav
protein
bind
receptor
host
cell
ctermin
unit
enabl
fusion
viral
membran
host
cell
membran
function
essenti
cov
propag
origin
studi
suggest
endosom
cystein
proteas
cathepsin
l
sole
requir
spike
activ
subsequ
sarscov
infect
simmon
et
al
notabl
cathepsin
depend
also
found
envelop
ebola
viru
filovirida
famili
chandran
et
al
nipah
viru
diederich
maisner
describ
later
numer
group
found
presenc
cathepsin
l
inhibitor
sprotein
sarscov
merscov
activ
gierer
et
al
matsuyama
et
al
shulla
et
al
zmora
et
al
consequ
inhibit
sarscov
growth
airway
epitheli
cell
achiev
combin
treatment
broadspectrum
serin
proteas
inhibitor
camostat
fig
cathepsin
inhibitor
ethyl
ester
est
kawas
et
al
base
observ
suggest
sarscov
enter
host
cell
via
two
distinct
pathway
one
use
ttsp
like
second
use
endosom
cathepsin
l
andor
b
spike
activ
interestingli
recent
studi
fresh
clinic
isol
human
cov
reveal
clear
prefer
host
cell
entri
via
wherea
passag
hela
cell
cathepsin
l
pathway
becam
import
shirato
et
al
howev
cell
cultur
viru
show
reduc
abil
replic
suggest
endosom
pathway
disadvantag
infect
human
base
result
author
suggest
target
rather
endosom
cathepsin
cov
infect
shirato
et
al
similar
tendenc
previous
found
anim
model
sarscov
infect
viral
spread
pathogenesi
prevent
tlsp
inhibitor
camostat
broadspectrum
vinylsulfonetyp
cystein
proteas
inhibitor
target
cathepsin
l
b
zhou
et
al
howev
author
argu
new
vinylsulfon
inhibitor
might
excel
lead
structur
develop
inhibitor
ebola
viru
entri
common
approach
proteas
inhibitor
develop
optim
natur
inhibitor
mutat
inhibitori
recognit
loop
portland
bioengin
serpintyp
inhibitor
contain
furinadapt
sequenc
instead
inhibitori
loop
inhibit
furin
k
valu
nm
slow
tightbind
manner
suppos
act
suicid
substrat
yield
inact
enzym
jean
et
al
also
inhibit
k
nm
k
nm
reduc
potenc
k
nm
express
cell
block
process
hiv
well
measl
viru
fusion
protein
thu
inhibit
viru
spread
anderson
et
al
watanab
et
al
base
reactiv
loop
numer
minipdx
peptid
prepar
acycl
disulfidebridg
cyclic
inhibit
furin
ic
valu
nm
nm
respect
basak
lotfipour
turkey
ovomucoid
third
domain
belong
famili
kazaltyp
inhibitor
normal
inactiv
serin
proteas
fold
prefer
neutral
residu
exchang
reactiv
site
loop
lead
moder
furin
inhibitor
associ
constant
k
lu
et
al
roughli
correspond
reciproc
dissoci
equilibrium
constant
nm
like
interalphainhibitor
protein
known
potent
serin
proteas
inhibitor
eg
trypsin
chymotrypsin
acrosin
first
isol
human
plasma
multicompon
complex
consist
two
heavi
one
light
chain
call
bikunin
link
via
chondroitin
linker
bikunin
possess
two
proteas
domain
kunitztyp
like
inhibit
furin
treatment
provid
signific
protect
anthrax
toxin
cell
cultur
studi
mice
opal
et
al
eglin
c
origin
isol
leech
hirudo
medicinali
belong
potato
inhibitor
famili
inhibit
sever
serin
proteas
eg
subtilisin
human
leukocyt
elastas
cathepsin
g
insert
multibas
recognit
site
mutat
result
strong
furin
inhibitor
k
valu
nm
komiyama
fuller
liu
et
al
addit
furin
inhibitor
design
mutat
homotetramer
glycoprotein
found
high
concentr
human
blood
potent
broadspectrum
proteas
inhibitor
uniqu
inhibit
mechan
proteas
mediat
cleavag
socal
bait
region
intern
sester
hydrolyz
trigger
conform
chang
proteas
enclos
steric
shield
substrat
barrett
starkey
replac
origin
sequenc
yield
potent
furin
inhibitor
block
process
von
willebrand
factor
van
rompaey
et
al
proteinas
inhibitor
first
report
furin
inhibitor
serpin
reactivesit
mutant
belong
group
ovalbumintyp
serpin
contain
two
furin
recognit
sequenc
within
segment
inhibit
furin
consist
two
step
start
rapid
format
loos
complex
follow
slow
isomer
stabl
complex
overal
k
valu
recombin
solubl
furin
vitro
pm
dahlen
et
al
recent
sever
specif
nanobodi
furin
describ
zhu
et
al
nanobodi
dromedaryderiv
singledomain
antigenbind
fragment
crystal
structur
one
nanobodi
complex
furin
addit
activesit
inhibitor
reveal
directli
bind
activ
site
fig
dahm
et
al
nevertheless
nanobodi
inhibit
furinmedi
cleavag
diphtheria
toxin
noncompetit
mechan
k
valu
approxim
activ
anthrax
toxin
zhu
et
al
obvious
block
cleavag
larger
proteinac
substrat
steric
hindranc
second
group
inhibitor
compris
variou
peptid
peptidomimet
due
rel
high
molecular
weight
neglig
oral
bioavail
stabil
problem
compound
first
choic
drug
develop
nevertheless
numer
inject
peptid
use
therapeut
applic
vliegh
et
al
first
potent
pc
inhibitor
irrevers
substrat
analogu
chloromethyl
keton
cmk
coval
bind
enzym
garten
et
al
hallenberg
et
al
wide
use
basic
pc
inhibitor
commerci
avail
deriv
decargvallysargcmk
fig
target
known
furinlik
pc
nanomolar
rang
garten
et
al
jean
et
al
cell
cultur
block
furincatalyz
cleavag
hiv
furthermor
first
crystal
structur
furin
obtain
complex
inhibitor
henrich
et
al
howev
cmk
suit
develop
vivo
studi
thrombin
inhibitor
dpheproargcmk
reveal
short
halflif
min
hanson
harker
segment
cmk
serv
design
analogu
contain
pseudo
peptid
bond
like
ketomethylen
inhibitor
k
valu
nm
furin
fig
anglik
far
endogen
pc
inhibitor
known
promin
role
play
autoinhibit
prodomain
zhong
et
al
furinlik
pc
synthes
zymogen
activ
autocatalyt
cleavag
within
prodomain
proseg
act
intramolecular
chaperon
need
correct
fold
regul
enzymat
activ
transport
within
secretori
pathway
moder
k
valu
nm
determin
complet
prodomain
furin
furthermor
inhibitor
reduc
prolifer
migrat
invas
cancer
cell
basak
et
al
sever
truncat
deriv
synthes
potent
one
dyyhfwhrgvtkrslsphrprhsr
inhibit
furin
inhibit
constant
moreov
peptid
deriv
prodomain
inhibit
furin
rang
basak
lazur
combinatori
peptid
librari
contain
approxim
million
hexapeptid
scan
identifi
inhibitor
instanc
inhibit
k
valu
nm
respect
wherea
moder
furin
inhibitor
inhibit
constant
hand
unprotect
analogu
hleuleuargvallysargoh
stronger
furin
affin
reduc
potenc
cameron
et
al
develop
new
peptidomimet
lead
structur
basic
pc
incorpor
decarboxyl
arginin
deriv
posit
start
agmatin
compound
k
nm
fig
equipot
noragmatin
analogu
approxim
potent
inhibitor
prepar
fig
inhibit
furin
k
valu
nm
similar
efficaci
reduc
potenc
becker
et
al
neglig
affin
trypsinlik
serin
proteas
thrombin
factor
xa
plasmin
modif
posit
tertleucin
penicillamin
provid
inhibitor
enhanc
potenc
becker
et
al
hard
et
al
consider
improv
affin
achiev
incorpor
basic
residu
becker
et
al
potent
analogu
fig
contain
paraguanidinomethyl
substitut
phenyl
ring
inhibit
furin
k
valu
pm
hard
et
al
inhibitor
similar
select
profil
describ
analogu
also
inhibit
low
picomolar
rang
best
knowledg
compound
potent
synthet
inhibitor
furinlik
pc
compound
enabl
determin
crystal
structur
complex
human
furin
fig
dahm
et
al
hard
et
al
nearli
ident
bind
mode
found
analog
inhibitor
contain
guanidinomethyl
substitut
metaposit
dahm
et
al
antivir
efficaci
inhibitor
andor
val
analogu
becker
et
al
hard
et
al
extens
studi
cell
cultur
infect
numer
furindepend
virus
signific
antivir
effect
found
hpaiv
strain
hard
et
al
lu
et
al
canin
distemp
viru
cdv
belong
paramyxovirida
close
relat
measl
viru
hard
et
al
moreov
inhibitor
reduc
replic
semliki
forest
chikungunya
viru
belong
alphavirus
furin
cleav
precursor
protein
tgn
hard
et
al
antivir
effect
also
found
flavivirus
like
west
nile
viru
kouretova
et
al
also
borna
diseas
viru
lennartz
et
al
furthermor
compound
strongli
protect
cell
anthrax
shiga
diphtheria
toxin
becker
et
al
hard
et
al
furthermor
inhibitor
fig
contain
induc
enediynyl
amino
acid
moieti
prepar
amino
carboxyl
group
unusu
amino
acid
coupl
peptid
sequenc
around
cleavag
site
within
prodomain
furin
compound
inhibit
furin
k
valu
nm
block
cleavag
fluorogen
peptid
deriv
spike
protein
human
sar
coronaviru
ic
valu
nm
basak
et
al
addit
ha
cleavag
site
influenza
viru
use
scaffold
develop
peptid
inhibitor
shiryaev
et
al
best
compound
tabl
inhibit
furin
k
valu
nm
wherea
pc
less
affect
optim
achiev
peptid
inhibit
furin
low
nanomolar
rang
reduc
potenc
k
nm
remacl
et
al
inhibitori
potenc
furin
could
enhanc
polyarginin
deriv
found
posit
scan
combinatori
l
dhexapeptid
librari
cameron
et
al
hexadarginin
tabl
inhibit
furin
k
valu
around
nm
rang
wherea
less
activ
elong
analogu
nonadarginineamid
compound
tabl
possess
significantli
improv
inhibit
constant
nm
contrast
analog
lpeptid
cleav
furin
dconfigur
found
fulli
stabl
cameron
et
al
kacprzak
et
al
anoth
attempt
synthes
potent
pc
inhibitor
base
monocycl
sunflow
trypsin
inhibitor
fig
fittler
et
al
therefor
backbon
use
start
point
sever
modif
like
implement
furin
cleavag
motif
truncat
inhibitor
potent
compound
tabl
seri
inhibit
furin
low
nanomolar
rang
k
nm
wherea
poorli
k
nm
trypsin
affect
moreov
peptidomimet
compound
contain
multileu
motif
describ
levesqu
et
al
aim
modif
discrimin
furin
select
deriv
seri
inhibit
ki
valu
nm
wherea
furin
less
affect
modif
polyethylen
glycol
differ
length
could
improv
select
profil
wherea
incorpor
residu
result
less
select
inhibitor
compar
furin
kwiatkowska
et
al
small
molecul
promis
candid
drug
develop
better
chanc
oral
bioavail
better
suit
address
intracellular
target
nevertheless
nonpeptid
pc
inhibitor
report
possess
moder
potenc
efficaci
deriv
obtain
within
seri
guanidinyl
deriv
potent
analogu
fig
inhibit
furin
inhibit
constant
nm
respect
wherea
affin
reduc
jiao
et
al
deriv
enabl
determin
crystal
structur
complex
human
furin
fig
dahm
et
al
surprisingli
two
inhibitor
molecul
bind
close
activesit
cleft
first
molecul
carbon
atom
green
bind
site
furin
without
address
pocket
bind
second
molecul
shown
carbon
atom
yellow
form
strong
polar
contact
furin
could
artifact
caus
unusu
high
inhibitor
concentr
use
crystal
reduct
peptid
bond
treatment
amid
precursor
boranetetrahydrofuran
provid
seri
multibas
piperazin
pyrrolidin
contain
deriv
like
fig
submicromolar
affin
weak
affin
furin
kowalska
et
al
among
seri
weakli
basic
guanylhydrazon
sever
compound
like
deriv
prepar
inhibit
furin
inhibit
constant
close
sielaff
et
al
even
monoguanylhydrazon
deriv
still
show
signific
furin
inhibit
k
valu
komiyama
et
al
compound
also
inhibit
rang
wherea
reduc
potenc
observ
despit
poor
vitro
potenc
cellperm
naphthofluorescein
deriv
k
valu
furin
abl
inhibit
furincatalyz
activ
remodel
proteas
lead
decreas
activ
cell
motil
cho
cell
treatment
also
reduc
invas
human
fibrosarcoma
cell
coppola
et
al
furthermor
furininhibit
dicoumarol
deriv
could
identifi
ht
compound
protect
cell
furinactiv
anthrax
toxin
inhibit
process
compound
noncompetit
bind
furin
inhibit
constant
komiyama
et
al
recent
seri
zinc
copper
ion
chelat
complex
describ
inhibit
furin
micromolar
rang
structur
suitabl
chelat
ligand
ttp
shown
fig
author
specul
activesit
histidin
might
coordin
zinc
copper
ion
interestingli
solvat
less
potent
chelat
form
wherebi
free
chelat
ligand
affect
furin
podsiadlo
et
al
one
approach
find
new
nonpeptid
furin
inhibitor
test
compound
natur
sourc
exampl
attempt
screen
chemic
constitu
medicin
use
plant
andrographi
paniculata
deriv
major
compon
andrographolid
sever
semisynthet
compound
test
potent
deriv
andrographolidetrisuccin
pyridinium
salt
fig
k
valu
basak
et
al
analog
cmk
inhibitor
furinrel
pc
irrevers
inhibitor
prepar
pasquato
et
al
substrat
analogu
backbon
deriv
cleavag
site
lassa
viru
lasv
glycoprotein
iyisrrl
base
sequenc
decrrllcmk
fig
decisrrllcmk
decyisrrllcmk
synthes
interestingli
show
vitro
higher
potenc
compar
longer
deriv
wherea
cell
cultur
experi
inhibitor
almost
equipot
cmk
deriv
abl
block
infect
lymphocyt
choriomening
viru
lcmv
chimera
lcmv
contain
lasv
glycoprotein
furthermor
enediynyl
peptid
synthes
base
amino
acid
sequenc
cleavag
site
known
substrat
sequenc
like
lasv
glycoprotein
prodomain
basak
et
al
potent
compound
fig
inhibit
k
valu
concept
mutat
therebi
optim
natur
serin
proteas
inhibitor
new
target
also
appli
develop
inhibitor
maisa
et
al
pullikotil
et
al
instead
multibas
furin
cleavag
site
motif
rk
xx
lt
seidah
chretien
introduc
overexpress
rrvl
variant
found
inhibit
cchfv
crimeancongo
hemorrhag
fever
viru
lasv
glycoprotein
matur
block
arenaviru
gpc
process
strong
antivir
effect
suppress
celltocel
spread
format
viral
particl
micromolar
concentr
wildtyp
proseg
need
inhibit
enzym
vitro
proseg
amino
acid
exchang
potent
mutant
inhibit
cleavag
cchfv
pregc
pullikotil
et
al
role
cholesterol
fatti
acid
synthesi
mind
highthroughput
screen
conduct
identifi
lead
structur
lower
plasma
cholesterol
triglycerid
hay
et
al
base
screen
result
improv
deriv
prepar
potent
compound
studi
fig
inhibit
ic
valu
nm
howev
less
potent
analogu
use
evalu
lower
molecular
weight
lipophil
revers
competit
inhibitor
ic
valu
nm
furthermor
highli
select
serin
proteas
like
trypsin
plasmin
kallikrein
furin
inhibit
compound
howev
suffer
rapid
clearanc
poor
oral
bioavail
rat
inhibit
block
cleavag
glycoprotein
oldworld
arenavirus
lasv
lcmv
result
reduc
viru
replic
infect
cell
cultur
urata
et
al
interestingli
escap
variant
could
detect
treatment
inhibitor
studi
extend
sever
newworld
arenavirus
like
junin
guanarito
viru
also
effici
block
glycoprotein
process
viru
product
pasquato
et
al
set
nonpeptid
isocoumarinyl
sulfon
deriv
test
howev
one
compound
fig
show
weak
inhibit
k
basak
et
al
sever
known
serin
proteas
inhibitor
among
aebsf
benzen
sulfonylfluorid
paminobenzamidin
fig
well
inhibitor
furin
furinrel
pc
like
decrvkrcmk
test
signific
inhibit
found
dci
compound
fig
exhibit
slow
irrevers
bind
mode
appar
inhibit
constant
bodvard
et
al
numer
viral
surfac
protein
cleav
endosom
cystein
proteas
papainlik
cathepsin
l
activ
ebola
viru
ebov
glycoprotein
gp
chandran
et
al
nipah
viru
f
protein
diederich
et
al
despit
contradictori
report
cathepsin
might
also
involv
gp
activ
coronavirus
zhou
et
al
contrast
major
serin
proteas
inhibitor
cystein
proteas
inhibitor
achiev
potenc
coval
modif
target
enzym
revers
irrevers
siklo
et
al
basic
exampl
typic
cystein
proteas
inhibitor
provid
paragraph
classic
warhead
lead
rel
specif
irrevers
inhibit
cystein
proteas
epoxysuccin
vinylsulfon
allylsulfon
wherea
chloromethyl
diazomethyl
keton
react
cystein
serin
proteas
archetyp
epoxysuccin
fig
isol
aspergillu
japonicu
form
thioether
bond
activesit
cystein
hanada
et
al
nonselect
inhibitor
nearli
cystein
cathepsin
except
cathepsin
c
turk
et
al
mani
analogu
prepar
replac
leucylagmatin
segment
hydrophob
ethyl
ester
prodrug
reach
clinic
phase
iii
trial
satoyoshi
peptid
vinylsulfon
repres
addit
class
wide
use
cystein
proteas
inhibitor
includ
numer
cathepsin
activesit
cystein
attack
michael
acceptor
like
vinylsulfon
becom
irrevers
alkyl
instanc
cathepsin
l
b
rapidli
inactiv
inhibitor
secondord
rate
constant
k
inactk
respect
palmer
et
al
consider
inhibit
ebov
gp
sarscov
sprotein
cleavag
observ
close
analogu
cell
cultur
like
compound
howev
compound
complet
inact
lethal
sarscov
mous
model
zhou
et
al
consider
slower
inactiv
cathepsin
b
k
ob
cystein
proteas
found
allylsulfon
numer
analogu
indic
reduc
electrophil
allylsulfon
segment
fennel
et
al
peptid
chloromethyl
diazomethyl
keton
power
et
al
also
effect
vitro
cystein
proteas
inhibitor
howev
suffer
instabl
vivo
often
low
select
similar
done
field
serin
proteas
inhibitor
cystein
proteas
inhibitor
prepar
includ
fig
keton
moieti
analogu
attack
activesit
cystein
lead
coval
revers
thiohemiket
complex
addit
exampl
summar
recent
publish
review
siklo
et
al
probabl
promis
warhead
develop
coval
revers
cystein
proteas
inhibitor
nitril
group
nitril
react
activesit
cystein
form
thioimid
adduct
myriad
peptid
nitril
inhibitor
prepar
frizler
et
al
instanc
compound
inhibit
cathepsin
l
b
ic
valu
nm
nm
greenspan
et
al
potenc
consider
enhanc
four
five
order
magnitud
could
achiev
replac
carbon
posit
nitrogen
instanc
result
azanitril
bind
cathepsin
l
k
valu
pm
possess
similar
picomolar
potenc
cathepsin
l
et
al
cathepsin
k
inhibitor
odanacatib
reach
clinic
phase
iii
develop
develop
recent
cancel
due
side
effect
moreov
complet
nonpeptid
nitril
deriv
develop
compound
inhibit
cathepsin
l
k
valu
nm
fig
numer
cathepsin
inhibitor
prepar
past
howev
despit
proof
concept
studi
deeper
character
optim
antivir
limit
far
mainli
test
nonvir
applic
eg
cancer
therapi
osteoporosi
rheumatoid
arthriti
neurodegen
diseas
siklo
et
al
turk
et
al
zincdepend
host
metalloproteas
mmp
matrix
metalloproteas
adam
disintegrin
metalloproteas
famili
might
also
involv
entri
fusion
certain
virus
recent
describ
neurovirul
murin
cov
strain
phillip
et
al
moreov
consider
amount
ebov
gp
shed
metalloproteas
tace
dolnik
et
al
solubl
gp
activ
dendrit
cell
macrophag
caus
releas
pro
antiinflammatori
cytokin
affect
vascular
permeabl
dysregul
inflammatori
host
respons
seem
contribut
high
viru
pathogen
escuderoperez
et
al
result
suggest
inhibitor
metalloproteas
may
antivir
activ
although
clinic
trial
metalloproteas
inhibitor
treatment
variou
cancer
fail
broad
antiinflammatori
potenti
arous
new
interest
vandenbrouck
libert
far
inhibitor
address
viral
proteas
approv
treatment
certain
viru
infect
huge
arsen
excel
inhibitor
host
proteas
develop
past
treatment
chronic
diseas
hypertens
diabet
risk
thrombosi
inflammatori
ailment
cancer
reach
clinic
despit
loss
patent
protect
mani
fail
inhibitor
analogu
could
still
suitabl
shortterm
treatment
acut
lifethreaten
infecti
diseas
without
hamper
side
effect
might
develop
longterm
applic
one
import
prerequisit
success
drug
develop
identif
valid
target
viru
infect
relev
host
proteas
identifi
case
still
uncertainti
basic
research
target
identif
need
sinc
proteas
usual
belong
famili
similar
enzym
substitut
broadspectrum
inhibitor
could
toler
even
advantag
special
treatment
infecti
diseas
although
select
drug
usual
prefer
applic
minim
side
effect
ideal
host
proteas
inhibitor
use
combin
addit
drug
strategi
improv
antivir
efficaci
allow
use
reduc
concentr
therebi
minim
side
effect
develop
effect
toler
host
proteas
inhibitor
hope
expand
arsen
antivir
drug
futur
